Study finds injection of hormones can ease liver disease worsening in HIV carriers

Non-alcoholic fatty liver disease (NAFLD) is often associated with HIV, and in developed countries, 25% of people living with HIV also suffer from non-alcoholic fatty liver disease, a risk factor for liver deterioration and liver cancerHowever, there is no effective treatment for the diseaseThe project, led by DrColleen MHadigan, senior research physician at the NIAID Immunomodulation Laboratory, and DrSteven KGrinspoon, director of MGH Metabolism, tested whether teshamolin could reduce liver fat and NAFLD in HIV carriersOf the volunteers tested, 43 per cent had at least mild fibrosis, while 33 per cent met the diagnostic criteria for more severe NAFLD for non-alcoholic fatty hepatitis (NASH)Participants were randomly assigned to two groups, with 31 participants receiving 2 mg of teshamolin injections per day, while 30 participants received the same-looking placeboThe researchers then compared the liver health of two groups of patients after baseline and 12 months of treatmentresults showed that participants who received the treatment for samolin had better liver health than those who received a placeboThirty-five percent of patients treated with "Tisamolin" had normal "HFF" values, compared with only 4 percent of those receiving a placeboOverall, tissamolin had good tolerance and could reduce the participants' HFF value by 4.1% (compared to 37%)In addition, the levels of several blood markers (including alanine transaminase (ALT) associated with inflammation and liver damage decreased more significantly in patients taking teshamolin either disease (ALT) than in placeboGiven these positive results, the researchers recommend extending the adaptation to Chamolin to include people diagnosed with HIV with NAFLDThey also recommend edi-shamlin to determine whether tisamolin can help prevent severe liver disease in people living with HIV in the long termsource: Drug reverses signs of liver disease in people living with HIV